Stavanger University Hospital Inflammatory Bowel Disease Trial
NCT01551563 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 700
Last updated 2025-05-16
Summary
The study aims at studying the outcomes of a protocol-based handling of newly diagnosed Inflammatory bowel disease ( IBD ) patients within a defined uptake area in Norway. It is a descriptive study and no hypothesis is predefined.
Cytokine studies, QoL and fatigue assessment will be included for hypothesis-generating purposes.
Conditions
Sponsors & Collaborators
-
Helse Stavanger HF
lead OTHER_GOV
Principal Investigators
-
Tore Grimstad, PhD · Helse Stavanger HF
Eligibility
- Min Age
- 16 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-04-30
- Primary Completion
- 2026-12-31
- Completion
- 2030-12-31
Countries
- Norway
Study Locations
More Related Trials
-
Inflammatory Bowel Disease(IBD), Treatment Response
NCT05350644 ·Status: TERMINATED
-
Evaluation of Molecular Mechanisms of Non-response to Therapy in Patients With Inflammatory Bowel Disease
NCT05733845 ·Status: RECRUITING ·Phase: NA
-
Improving the Health Care in Inflammatory Bowel Disease.
NCT02770599 ·Status: UNKNOWN
-
Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?
NCT03011268 ·Status: COMPLETED ·Phase: NA
-
Immunological Characteristics of Preclinical IBD
NCT05698745 ·Status: RECRUITING
-
Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease. A Cross Sectional Study in Norway.
NCT01524328 ·Status: COMPLETED
-
Deep Endoscopic Remission Assessed by a Surrogate Biomarker in Patients With Inflammatory Bowel Disease
NCT01861288 ·Status: COMPLETED
-
Does the Microbiome in IBD Change Alongside Special Treatment Scenarios?
NCT02526251 ·Status: COMPLETED
-
Predictors of Prognosis in IBD Patients
NCT05653011 ·Status: RECRUITING
-
Remote Monitoring of IBD
NCT05886322 ·Status: UNKNOWN
-
Improving Treatment of Inflammatory Bowel Diseases Through Better Understanding Infliximab Drug and Antibody Levels
NCT01787786 ·Status: WITHDRAWN
-
Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease
NCT03801928 ·Status: COMPLETED
-
Relationship Between Baseline Burden of Disease and TDM in Ulcerative Colitis
NCT03808506 ·Status: WITHDRAWN
-
A Diagnostic Accuracy Study Testing Fecal Biomarkers In Comparison To Endoscopic Examination
NCT04849936 ·Status: UNKNOWN
-
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
NCT03251118 ·Status: ACTIVE_NOT_RECRUITING
-
Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: EPIC Study
NCT05280405 ·Status: UNKNOWN ·Phase: PHASE4
-
Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy
NCT00851565 ·Status: UNKNOWN ·Phase: PHASE4
-
Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease
NCT03376230 ·Status: TERMINATED
-
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
NCT02508012 ·Status: COMPLETED ·Phase: NA
-
Immunological Profiles in Inflammatory Bowel Disease
NCT03366090 ·Status: UNKNOWN
-
Long-term Functional Outcome of Children With Inflammatory Bowel Disease
NCT02152241 ·Status: COMPLETED
-
Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)
NCT01971970 ·Status: COMPLETED
-
Interactions Between Immune Cells of Intestinal Mucosa or Peripheral Blood With the Extracellular Matrix in Inflammatory Bowel Disease (IBD)
NCT00915044 ·Status: UNKNOWN
-
A Prospective Longitudinal Study of Fecal Microbiome and Calprotectin to Predict Relapse in Patients With IBD
NCT04079335 ·Status: UNKNOWN
-
Research and Follow-up of the Determinants of the Progression and Complications of Inflammatory Bowel Diseases Treated or Not With Immunosuppressants.
NCT07172945 ·Status: NOT_YET_RECRUITING ·Phase: NA